Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1902 Target Snapshot

Peptidyl-prolyl cis-trans isomerase FKBP1A · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
932Compounds
111Assays
11Approved Drugs
1,024.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Peptidyl-prolyl cis-trans isomerase FKBP1A shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P62942. Start with breast cancer, then reuse UniProt P62942 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with breast cancer, then reuse UniProt P62942 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 3 linked drugs
Open source guide
Disease program
breast cancer

Peptidyl-prolyl cis-trans isomerase FKBP1A shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include EVEROLIMUS, SIROLIMUS, TEMSIROLIMUS. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Peptidyl-prolyl cis-trans isomerase FKBP1A as ChEMBL target CHEMBL1902, mapped to UniProt P62942. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Peptidyl-prolyl cis-trans isomerase FKBP1A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1902
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P62942
Peptidyl-prolyl cis-trans isomerase FKBP1A
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Peptidyl-prolyl cis-trans isomerase FKBP1A is the right protein anchor across sources, using UniProt P62942 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why breast cancer is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NamePeptidyl-prolyl cis-trans isomerase FKBP1A
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP62942
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPeptidyl-prolyl cis-trans isomerase FKBP1A
UniProt AccessionP62942
Component TypeProtein
Sequence Length108 aa

Peptidyl-prolyl cis-trans isomerase FKBP1A

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Peptidyl-prolyl cis-trans isomerase FKBP1A, mapped to UniProt P62942. Sequence length is 108 aa.

Mapped IDP62942
Review namePeptidyl-prolyl cis-trans isomerase FKBP1A
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Peptidyl-prolyl cis-trans isomerase FKBP1A shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
breast cancer
3 linked drugs · 3 direct · 3 efficacy
Linked drugEVEROLIMUS
Linked drugSIROLIMUS
Linked drugTEMSIROLIMUS
Approved-linked Approved
cancer
3 linked drugs · 3 direct · 3 efficacy
Linked drugEVEROLIMUS
Linked drugSIROLIMUS
Linked drugTEMSIROLIMUS
Approved-linked Approved
Mantle cell lymphoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugEVEROLIMUS
Linked drugSIROLIMUS
Linked drugTEMSIROLIMUS
Approved-linked Approved
neoplasm
3 linked drugs · 3 direct · 3 efficacy
Linked drugEVEROLIMUS
Linked drugSIROLIMUS
Linked drugTEMSIROLIMUS
Approved-linked Approved
pancreatic carcinoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugEVEROLIMUS
Linked drugSIROLIMUS
Linked drugTEMSIROLIMUS
Approved-linked Approved
renal cell carcinoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugEVEROLIMUS
Linked drugSIROLIMUS
Linked drugTEMSIROLIMUS
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include EVEROLIMUS, SIROLIMUS, TEMSIROLIMUS. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebreast cancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

11
Approved
3
Phase II
Assay Mix

Activity Type Distribution

IC50244.0
KI427.0
EC5045.0
KD308.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL6367 11.0 Ki 0.01 Preclinical
CHEMBL5634031 10.52 Kd 0.03 Preclinical
CHEMBL413 9.89 Kd 0.13 Approved
CHEMBL269732 9.7 Kd 0.2 Approved
CHEMBL413 9.7 Ki 0.2 Approved
CHEMBL5935211 9.68 Kd 0.21 Preclinical
CHEMBL5275279 9.57 EC50 0.27 Preclinical
CHEMBL4449096 9.52 Ki 0.3 Preclinical
CHEMBL6063426 9.47 Kd 0.34 Preclinical
CHEMBL262778 9.4 IC50 0.4 Preclinical
Distribution

pChEMBL Value Distribution

57
5.0
79
5.5
131
6.0
120
6.5
89
7.0
88
7.5
85
8.0
33
8.5
41
9.0
9
9.5
pChEMBL
Approved Drugs

Approved Drugs

SIROLIMUS
CHEMBL413
Approved 1999
Properties Compare Identifier
TACROLIMUS ANHYDROUS
CHEMBL269732
Approved 1994
Properties Compare Identifier
TACROLIMUS
CHEMBL3989887
Approved 1994
Properties Compare Identifier
CYCLOSPORINE
CHEMBL160
Approved 1983
Properties Compare Identifier
Assay Landscape

Assay Landscape

111
Total Assays
744
Tested Compounds
3
Assay Types
Binding — 101 assays, 744 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 83 611 6.9
cell-based format 11 41 6.6
assay format 7 92 5.9
ADME — 9 assays, 22 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 7 15 6.9
assay format 1 2 7.3
single protein format 1 5 6.1
Functional — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine